Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Burkitt Lymphoma 15Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Accelerated Phase 1HTLV-I Infections 1Down Syndrome 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Prostatic Neoplasms × deltacortene × 90 days × Clear all
NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT06378866 2026-04-20

DIVINE

Mayo Clinic

Phase 2 Recruiting
532 enrolled
Genitourinary

Prostatic Neoplasms

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT03360721 2026-03-16

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

University of California, Davis

Phase 2 Recruiting
75 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡